

●► **Sanofi** *(FDA, Approval)*
Sanofi's Tzielid gets FDA approval to treat patients recently diagnosed with Stage 3 type 1 diabetes

●► **Eli Lilly** *(FDA, Approval)*
FDA grants approval to Eli Lilly's EBGLYSS 250 mg/2 mL SC injection for maintenance dosing to treat moderate-to-severe atopic dermatitis

●► **AstraZeneca** *(FDA, Approval)*
AstraZeneca's TRUQAP, in combination with abiraterone and prednisone, gains FDA approval to treat adults with mAPMN/S prostate cancer

●► **Novo Nordisk** *(UK, Approval)*
MHRA grants approval to Novo Nordisk's WEGOVY as an injectable treatment adjunct to a reduced-calorie diet and increased physical activity for obesity



●▶ **AstraZeneca**

(FDA, Priority Review)

FDA accepts AstraZeneca's ULTOMIRIS sBLA for Priority Review to treat adults with IgA nephropathy

●▶ **Genentech**

(FDA, Priority Review)

Genentech's sBLA for TECENTRIQ and TECENTRIQ HYBREZA in combination with chemotherapy in stage III dMMR or MSI-H colon cancer receives Priority Review from the FDA

●▶ **GSK**

(FDA, EMA, Orphan Drug)

GSK's momelotinib gets Orphan Drug designation from the FDA and EMA for the treatment of VEXAS syndrome

●▶ **Chiesi**

(Acquisition)

Chiesi acquires KalVista Pharmaceuticals to contribute to the growth of the Rare Diseases business unit, with assumed ownership of EKTERLY



- ▶ **GSK** *(Acquisition)*
GSK makes agreement to acquire Nuvalent along with its three products in lung cancer in a single transaction

- ▶ **PharmaEssentia** *(Acquisition)*
PharmEssentia acquires FORUS Therapeutics for US \$36.5M, now positioned to accelerate BESREMI across Canada

- ▶ **Teva** *(Acquisition)*
Teva acquires Emalex Biosciences, strengthening its late-stage neuroscience pipeline with ecopipam, advancing its pivot to growth strategy

- ▶ **WestGene Biopharma** *(Collaboration)*
WestGene Biopharma and Cartesian Therapeutics collaborate to develop in vivo CAR-T and TCE therapies based on mRNA and tLNP technologies for autoimmune diseases



AlzeCure Pharma*(Collaboration)*

AlzeCure Pharma collaborates with Eli Lilly for the global rights of ACD680, an Alzheimer's project with a total deal value exceeding \$1 billion USD excluding royalty payments

Roche*(Collaboration)*

Roche collaborates with Nurix Therapeutics to co-develop and co-commercialize NX-5948, providing a cross-therapeutic opportunity for Roche to extend pipeline reach in immunology and neurology

Takeda*(Phase 3, Results)*

Takeda's TAK-279 demonstrates superiority over deucravacitinib for primary and all key secondary endpoints with PASI 90 response and sPGA 0 at Week 16 in the Phase 3 LATITUDE Atlas study

Merck*(Phase 3, Results)*

Merck's Phase 3 trials, ISLEND-1 and ISLEND-2, investigating islatravir/lenacapvir in HIV show non-inferiority to standard of care antiretroviral therapy with comparable safety profile

